Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial
Wolfgang Stremmel1, Robert Ehehalt, Frank Autschbach
1Department of Gastroenterology, University Hospital Heidelberg, Heidelberg, Germany. wolfgang.stremmel@med.uni-heidelberg.de
Annals of Internal Medicine
|November 3, 2007
Summary
Phosphatidylcholine supplementation aids steroid withdrawal in ulcerative colitis patients when other treatments fail. This study found phosphatidylcholine significantly improved steroid-free remission rates compared to placebo.
Area of Science:
- Gastroenterology
- Clinical Pharmacology
Background:
- Ulcerative colitis (UC) management faces challenges when immunosuppressants fail, with limited alternatives to long-term corticosteroid therapy.
- Reduced colonic mucus phosphatidylcholine levels are implicated in UC pathogenesis.
Purpose of the Study:
- To evaluate the efficacy of phosphatidylcholine in facilitating steroid withdrawal in chronic steroid-refractory UC patients.
Main Methods:
- A randomized, double-blind, placebo-controlled trial involving 60 adult patients with active, steroid-refractory UC.
- Patients received either phosphatidylcholine or a placebo for 12 weeks.
- Primary endpoint: achieving complete steroid withdrawal with clinical improvement.
Main Results:
- 50% of phosphatidylcholine recipients achieved the primary endpoint versus 10% of placebo recipients (P=0.002).
- 80% of phosphatidylcholine recipients discontinued steroids without exacerbation, compared to 10% of placebo recipients (P<0.001).
- Mild bloating was the most common side effect.
Conclusions:
- Phosphatidylcholine demonstrates potential in reducing corticosteroid dependence in steroid-refractory UC.
- Further long-term studies are needed to confirm the sustainability of steroid withdrawal.
Related Concept Videos
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
2.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.3K
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.7K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.7K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
34
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal...
34